Kai Yu Jen - Concepedia

Author

Kai Yu Jen

Cleveland Clinic ORCID

Also Known As

K Jen, K. Jen, Kai Yu Jen

122

Publications

225

Citations

H-Index

Concepts

All Affiliations

Cleveland Clinic The University of Texas MD Anderson Cancer Center Memorial Sloan Kettering Cancer Center Massachusetts General Hospital University of Michigan

About

Kai Yu Jen is an author at Cleveland Clinic specializing in cancer research, tumor biology, and medicine.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	3	3	49
2	Pathology	3	3	49
3	Pharmacology	2	2	25
4	Cell Biology	1	1	24
5	Hepatology	1	1	14

Kai Yu Jen

Publications

214

Citations

H-Index

Page 1

	Year	Citations
RLY-4008, the First Highly Selective FGFR2 Inhibitor with Activity across <i>FGFR2</i> Alterations and Resistance Mutations Vivek Subbiah, Vaibhav Sahai, Dejan Maglic, Cancer Discovery	2023	103
Two‐phase appearance of oral epithelial dysplasia resulting from focal proliferation of parabasal cells and apoptosis of prickle cells Mei Syafriadi, Jun Cheng, Kai Yu Jen, Journal of Oral Pathology and Medicine	2005	30
Parenchymal-stromal switching for extracellular matrix production on invasion of oral squamous cell carcinoma Hamdy Metwaly, Satoshi Maruyama, Manabu Yamazaki, Human Pathology Tumor BiologyMedicineOral CavityPathologyOral Biology	2012	24
CD45RB Ligation Inhibits Allergic Pulmonary Inflammation by Inducing CTLA4 Transcription Kai Yu Jen, Monica Campo, Hongzhen He, The Journal of Immunology	2007	22
First-in-human study of highly selective FGFR2 inhibitor, RLY-4008, in patients with intrahepatic cholangiocarcinoma and other advanced solid tumors. Alison M. Schram, Suneel D. Kamath, Anthony B. El-Khoueiry, Journal of Clinical Oncology PathologyCholangiopathiesFirst-in-human StudySelective Fgfr2 InhibitorTumor Biology	2021	14
Abstract P02-02: First results of RLY-4008, a potent and highly selective FGFR2 inhibitor in a first-in-human study in patients with FGFR2-altered cholangiocarcinoma and multiple solid tumors Lipika Goyal, Mitesh J. Borad, Vivek Subbiah, Molecular Cancer Therapeutics PathologyPharmacotherapySelective Fgfr2 InhibitorTumor BiologyFgfr2 Driver	2021	11
Abstract IA006: Clinical activity of lirafugratinib (RLY-4008), a highly selective FGFR2 inhibitor, in patients with advanced FGFR2-altered solid tumors: The ReFocus study Alison M. Schram, Vivek Subbiah, Chih‐Yi Liao, Molecular Cancer Therapeutics	2023	10

Page 1